Clinical trial
Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma…
NCT00239200 · University of Michigan Rogel Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00239200 |
|---|---|
| Title | Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus |
| Official title | Lapatinib (GW572016) a Dual Inhibitor of EGFR and ErbB2, for Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus |
| Intervention type | Drug |
| Interventions | Lapatinib |
| Enrollment | 29 |
| Start date | Oct 1, 2005 |
| Primary completion | Jun 1, 2006 |
| Completion | Sep 1, 2007 |
| First posted | Oct 14, 2005 |
| Last update posted | Jul 30, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: